# Metformin improves RAN protein pathology, alternative splicing, and behavioral phenotypes in SCA8 mice

## TL;DR

Metformin improves symptoms and pathology in SCA8 mice, suggesting potential for treating CAG•CTG expansion diseases.

## Contribution

Metformin reduces RAN proteins and neuroinflammation in SCA8 mice, offering a novel therapeutic approach.

## Key findings

- Metformin improves ambulatory performance in SCA8 mice using behavioral tests.
- Metformin reduces RAN protein levels and splicing abnormalities without altering RNA levels.
- Metformin decreases neuroinflammation and glial activation in SCA8 mice.

## Abstract

Spinocerebellar ataxia type 8, a debilitating neurological disease with no effective treatment, is caused by a CAG•CTG expansion mutation. In SCA8 mice, metformin decreases repeat-associated non-AUG proteins and neuroinflammation, improves behavior, and partially corrects splicing abnormalities.

Spinocerebellar ataxia type 8 (SCA8) is a member of a group of dominantly inherited, debilitating neurological diseases caused by CAG•CTG expansions for which there are no effective treatments. RAN translation, which was discovered in SCA8, has previously been shown to occur across CAG and CUG expansion transcripts, making treatments for SCA8 potentially relevant to a broad group of diseases, including SCA1, SCA2, SCA3, SCA6, SCA7, SCA12, Huntington’s disease, and myotonic dystrophy type 1. In addition, CUG and CAG expansion transcripts have been reported to cause RNA gain-of-function effects. Using SCA8 BAC transgenic mice as a model for CAG•CTG expansion diseases, we now show that metformin improves ambulatory performance using rotarod, DigiGait, and open-field testing. At the molecular level, metformin-treated mice show reduced RAN protein levels and improved splicing, without altering sense or antisense RNA levels. Metformin-treated mice also show decreased neuroinflammation, with reduced astrogliosis and fewer activated microglia. These data provide strong preclinical support for testing metformin in clinical trials for SCA8 and potentially the broader group of CAG•CTG repeat expansion disorders.